Compositions for making and using anti-Myostatin antibodies
Aspects of the present disclosure relate to antibodies that specifically bind proMyostatin and/or latent Myostatin and uses thereof.
1. A host cell comprising a polynucleotide encoding an antibody or antigen-binding fragment thereof that specifically binds to pro/latent myostatin, binds to pro/latent myostatin with a decreased affinity at an acidic pH as compared to a neutral or physiological pH, and inhibits myostatin signaling after binding, wherein the host cell is prepared by the steps of:
(i) screening for an antibody or antigen-binding fragment that specifically binds to pro/latent myostatin as compared to mature myostatin and/or another member of the transforming growth factor beta family;
(ii) screening the antibody or antigen-binding fragment thereof for inhibition of myostatin signaling;
(iii) assaying the antibody or antigen-binding fragment for binding to pro/latent myostatin wherein the antibody or fragment binds to pro/latent myostatin with a decreased affinity at an acidic pH as compared to a neutral or physiological pH;
(iv) isolating a polynucleotide encoding the antibody or antigen-binding fragment; and
(v) incorporating the polynucleotide in the host cell.
2. The host cell of claim 1 , wherein the host cell is a mammalian cell.
3. The host cell of claim 1 , wherein the host cell is a NSO cell, a HEK293 cell, or a CHO cell.
4. The host cell of claim 1 , wherein step (ii) comprises screening the antibody or antigen-binding fragment thereof using a cell-based assay.
5. The host cell of claim 4 , wherein the cell-based assay is a reporter assay.
6. The host cell of claim 5 , wherein the reporter assay is a SMAD-based reporter assay.
7. A cell line comprising the host cell of claim 1 .
8. The cell line of claim 7 , wherein the cell line is a mammalian cell line.
9. The cell line of claim 7 , wherein the cell line is a NSO cell line, a HEK293 cell line, or a CHO cell line.